Comparison of the effectiveness and safety of different dose of ropivacaine in patients undergoing cesarean section with combined spinal-epidural anesthesia at plateau area

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032357

Enrollment

Unknown

Registered

2020-04-26

Start date

2020-05-06

Completion date

Unknown

Last updated

2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cesarean section

Interventions

Group A:0.5% ropivacaine 8mg

Group B:0.5% ropivacaine 10mg

Group C:0.5% ropivacaine 12mg

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Cesarean section and combined spinal and epidural anesthesia were performed. 2. 20 years old <= age <= 45 years old;

Exclusion criteria

Exclusion criteria: 1. Long term ( >= 10 years) hypertension, diabetes, cardiac insufficiency (NYHA > Level 2) and renal insufficiency (GFR < 60ml / min) were found; 2. The patient is allergic to ropivacaine; 3. Refuse to sign informed consent.

Design outcomes

Primary

Measure	Time frame
blood pressure;heart rate;Blood oxygen;	—

Secondary

Measure	Time frame
Anesthesia plane;Time to reach anesthesia level;Lidocaine dosage;Ephedrine dosage;Apgar score of 1 min newborn;Apgar score of 5 min newborn;Anesthetic effect;Intraoperative complications;Postoperative complications;	—

Countries

China

Contacts

Public ContactLiting Kuang

The First Affiliated Hospital of Sun Yat-Sen University

samk2002@qq.com+86 13560365048

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026